CA
TEVA icon

Cresta Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Cresta Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-98
Closed -$3.06K – 143
2025
Q4 		$3.06K Buy
+98
New +$2.41K ﹤0.01% 146

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cresta Advisors's TEVA Position: Q1 2026 in Review

Cresta Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 98 shares — an estimated $3.06K sold.

Cresta Advisors first reported a position in TEVA in Q4 2025 and held it in 1 quarter. The position peaked at $3.06K in Q4 2025. 652 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Cresta Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cresta Advisors sold 98 Teva Pharmaceuticals shares in Q1 2026, an estimated $3.06K.
  • Cresta Advisors first reported a position in Teva Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Cresta Advisors's Teva Pharmaceuticals position peaked at $3.06K in Q4 2025.
  • 652 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Cresta Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.